外源性胰高血糖样素肽-1治疗对糖尿病伴高血压患者血压变异性的影响  

Impact of exogenous glucagon-like peptide-1 hormone therapy on blood pressure variability in diabetes patients with hypertension

作　　者：吴荔茗[1] 那日苏[1] 邱凌[1] 丁新[1] 郑旭磊[1] 刘巧蕊[1] 马聪[1] 盛宏光[1] 刘志文[1] 

机构地区：[1]上海市徐汇区中心医院内分泌科,上海200031

出　　处：《临床和实验医学杂志》2016年第5期451-453,共3页Journal of Clinical and Experimental Medicine

摘　　要：目的探讨外源性胰高血糖样素肽-1治疗对糖尿病伴高血压患者血压变异性的影响。方法选择2型糖尿病伴高血压患者179例,随机分为对照组90例,研究组89例。对照组仅采用常规治疗,研究组在常规治疗基础上采用利拉鲁肽注射治疗,比较两组治疗6个月后血压变异性的变化。结果治疗6个月后研究组24 h平均收缩压、24 h收缩压变异性、白昼收缩压变异性、夜间收缩压变异性显著低于对照组(P<0.05)。治疗6个月后研究组较对照组夜间收缩压下降百分率显著增加,非杓型血压患者比率显著降低(P<0.05)。结论外源性胰高血糖样素肽-1可降低糖尿病伴高血压患者的血压变异性与非杓型血压患者比率。Objective To investigate the impact of exogenous glucagon- like peptide- 1（ GLP- 1） on blood pressure variability in diabetes patients with hypertension. Methods A total of 179 patients with type 2 diabetes and hypertension were collected and divided into two groups. Control group（ n = 90） received conventional treatment; in addition to conventional treatment,patients in study group（ n = 89） also received liraglutide injections. The change in blood pressure variability was compared between two groups after six months treatment. Results After6 months of treatment,the mean 24 h systolic blood pressure,24 h SBPV,d SBPV,n SBPV in study group were significantly lower than control group（ P〈0. 05）; and nocturnal systolic blood pressure was decreased significantly and the percentage of non- dipper blood pressure was significantly reduced in comparison with control group（ P〈0. 05）. Conclusion Exogenous GLP- 1 can reduce blood pressure variability and the proportion of non- dipper blood pressure in patients with diabetes and hypertension.

关 键 词：糖尿病 高血压 血压变异 胰高血糖样素肽-1 

分 类 号：R544.1[医药卫生—心血管疾病]